Related Experiment Video
Updated: Jul 6, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Beta1- and beta2-adrenoceptor polymorphisms and cardiovascular diseases
1Department of Pathophysiology, University of Essen School of Medicine, D-45147 Essen, Germany.
Fundamental & Clinical Pharmacology
|March 21, 2008
Summary
Beta-adrenergic receptor (AR) gene polymorphisms do not cause cardiovascular diseases but may influence drug responses. Specific beta(1)-AR genotypes predict patient responsiveness to beta-blocker treatments, aiding personalized medicine approaches.
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Molecular Biology
Background:
- Beta(1)- and beta(2)-adrenoceptors (AR) are crucial for cardiovascular regulation.
- These AR subtypes exhibit genetic variations, including single nucleotide polymorphisms (SNPs).
- Key SNPs in beta(1)-AR (Ser49Gly, Arg389Gly) and beta(2)-AR (Arg16Gly, Gln27Glu, Thr164Ile) affect receptor function in vitro.
Purpose of the Study:
- To review the association between beta(1)- and beta(2)-AR polymorphisms and cardiovascular diseases.
- To explore the potential of these polymorphisms in predicting drug responses.
- To summarize current evidence on the clinical relevance of AR gene variations.
Main Methods:
- Review of existing studies investigating the relationship between AR polymorphisms and cardiovascular diseases.
- Analysis of in vitro data on the functional consequences of specific AR SNPs.
- Synthesis of findings regarding the impact of AR genotypes on drug efficacy and patient outcomes.
Main Results:
- Beta(1)- and beta(2)-AR polymorphisms are not considered primary causes of hypertension, coronary artery disease, or heart failure.
- The Arg389Gly polymorphism in beta(1)-AR may predict responsiveness to beta-blockers, with Arg389 homozygotes being good responders and Gly389 homozygotes being poor responders.
- The Thr164Ile polymorphism in beta(2)-AR is associated with blunted responses to beta(2)-AR stimulation.
Conclusions:
- Beta-AR polymorphisms do not directly cause cardiovascular diseases but can influence therapeutic responses.
- Genotyping for beta(1)-AR polymorphisms, particularly Arg389Gly, may allow prediction of patient response to beta-blocker therapy.
- Further large-scale prospective studies are required to confirm the clinical utility of these pharmacogenetic findings.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:26Adrenergic Receptors: β Subtype
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:27Adrenergic Receptors (Adrenoceptors): Classification
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
01:31Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...